Long-Term Survival Prognostics in Glioblastoma Multiforme

Glioblastoma multiforme (GBM) remains one of the most aggressive adult brain tumours, with median survival rarely exceeding 15 months. Yet a subset of patients—often classified as long-term survivors—live beyond three or even five years. Understanding prognostic determinants of such survival outliers has become a central theme of translational neuro-oncology. Recent efforts have elucidated an array of clinical, radiological, molecular and epigenetic features that collectively shape patient trajectories. Clinical attributes such as younger age at diagnosis and higher functional status combine with molecular signatures—including isocitrate dehydrogenase (IDH) mutation status and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation—to inform individual risk profiles. Advances in high-throughput proteomics and DNA methylome analysis have unveiled novel biomarkers, while radiomics approaches applied to multiparametric MRI are refining non-invasive risk stratification. Integrative models that marry these diverse data streams promise enhanced predictive accuracy and may guide more tailored therapeutic interventions. As global research converges on these multi-modal prognostic frameworks, the prospect of improving long-term outcomes in GBM is shifting from aspiration towards tangible reality.

Research from Nature Portfolio

Explorations of the DNA methylation landscape have uncovered specific CpG sites whose methylation status correlates robustly with survival duration in GBM. Notably, hypermethylation at a locus overlapping the RE1 Silencing Transcription Factor binding motif has emerged as a discriminator between short-term and long-term survivors, suggesting a functional impact on transcriptional regulation of key survival pathways. Broader analyses of methylation interdependencies reveal methylation changes both near CpG islands—associated with downregulation of oncogenic signalling—and in gene-body regions, where hypomethylation may reduce somatic mutation rates. These insights illustrate how nuanced epigenetic alterations can serve as independent prognostic markers and may inform future stratification strategies.

Long-Term Survival Prognostics in Glioblastoma Multiforme publication trend

The graph below shows the total number of articles in long-term survival prognostics in glioblastoma multiforme across all publications each year (not limited to Nature Index journals).

Technical terms

DNA methylation: Addition of methyl groups to cytosine bases in DNA, affecting gene expression without altering sequence.

MGMT promoter methylation: Epigenetic silencing of the O6-methylguanine-DNA methyltransferase gene, associated with increased sensitivity to alkylating chemotherapy.

Proteomics: Large-scale study of proteins and their functions, used to identify novel biomarkers in tumour and serum samples.

Reactive oxygen species (ROS): Chemically reactive molecules containing oxygen, whose detoxification can influence tumour cell survival under therapy.

Radiomics signature: Quantitative descriptors extracted from imaging data, used to predict tumour behaviour and treatment response.

Progression-free survival: Interval from treatment initiation to tumour progression or recurrence, a measure of treatment efficacy.

Karnofsky Performance Status: Scale measuring a patient’s functional capacity, used to assess prognosis and guide clinical decision-making.

References

1. Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders’ Collaborative Consortium (EORTC 1419). European Journal of Cancer (2023).
2. Proteomics of tumor and serum samples from isocitrate dehydrogenase‐wildtype glioblastoma patients: is the detoxification of reactive oxygen species associated with shorter survival?. Molecular Oncology (2024).
3. Molecular features of glioblastomas in long-term survivors compared to short-term survivors—a matched-pair analysis. Radiation Oncology (2022).
4. Machine Learning Based on a Multiparametric and Multiregional Radiomics Signature Predicts Radiotherapeutic Response in Patients with Glioblastoma. Behavioural Neurology (2020).
5. Integrative analysis of DNA methylation suggests down-regulation of oncogenic pathways and reduced somatic mutation rates in survival outliers of glioblastoma. Acta Neuropathologica Communications (2019).
6. Unveiling new interdependencies between significant DNA methylation sites, gene expression profiles and glioma patients survival. Scientific Reports (2018).